This presentation will outline the pathobiology and visual phenotype of immune mediated optic neuropathies that include Multiple Sclerosis (MS), Neuromylitis optica spectrum disorders (NMOSD), and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Meet us at the 18th International Myopia Conference (IMC) in Rotterdam and see our Photorefractor and Keratometer!
In retinal vein occlusion (RVO), non-apoptotic expression of endothelial caspase-9 (EC Casp9) induces pathology including retinal edema, capillary ischemia, and neurodegeneration. Crystal Colón Ortiz presents mechanistic insights into EC Casp9 action, and the behavioral consequences such as contrast sensitivity decline.
Find us at booth #2523 in Denver! After more than 3 years, we cannot wait to connect with you in-person again.
Jana Remlinger et al. showed preserved visual function and ameliorated course of disease after anti-FcRn treatment in an experimental model using a monoclonal MOG-IgG to mimic MOGAD.
In this “OptoDrum Applications” video, Dr. Maximiliano Presa from The Jackson Laboratory presents results of his research in a model of Multiple Sulfatase Deficiency (MSD).
Scientists from Harvard Medical School were able to reverse the consequences of aging in the visual system, successfully treating optic nerve injury and glaucoma. Here is an overview of their 2020 study and it´s key findings.
Next week, on October 14th, it is world sight day, themed “#LoveYourEyes”, and the whole of October is blindness awareness month. Both events are meant to guide global attention to vision impairment and blindness, strengthen vision research, and improve access to eyecare worldwide.
Striatech offers new products for research on Myopia, a chronic progressive eye disease. It is estimated that by 2050, almost 50% of the world population will be myopic. But Myopia also leads to numerous secondary eye diseases that can even lead to blindness.
In this recent paper, Françoise Morin et al. show with our OptoDrum that a lack of histamine, unexpectedly, has no impact on the development and severity of Experimental Autoimmune Encephalomyelitis (EAE).